Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences CEO, Daniel P. O'Day, exercised stock options and sold a portion of the acquired shares on December 10, 2024.

Johanna Mercier, Chief Commercial Officer at Gilead Sciences, reported the acquisition of 3,752 shares of common stock through the vesting of restricted stock units and the disposition of 1,739 shares to cover tax obligations.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, received stock and restricted stock units on December 10, 2024, as part of his compensation.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, exercised stock options and sold shares according to a pre-arranged trading plan.

Gilead Sciences' Chief Medical Officer, Merdad Parsey, engaged in multiple stock option exercises and sales on November 27, 2024.

Gilead Sciences director Jeffrey Bluestone exercised stock options and sold shares on November 26, 2024.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold 5,000 shares of common stock at a price of $91.28 per share on November 6, 2024, according to a Form 4 filing with the SEC.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, exercised stock options and sold shares of common stock on November 6, 2024, according to a Form 4 filing with the SEC.

Deborah H. Telman, EVP of Corporate Affairs & GC at Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.

Chief Medical Officer of Gilead Sciences, Merdad Parsey, sold 2,000 shares of common stock at a price of $83.83 per share on October 1, 2024, according to a Form 4 filing with the SEC.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, exercised stock options and sold shares on September 12, 2024, according to a Form 4 filing with the SEC.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold a portion of her holdings in common stock under a pre-arranged Rule 10b5-1 trading plan.

EVP Deborah H. Telman reports stock transactions involving Gilead Sciences common stock, including the vesting and disposal of restricted stock units.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Gilead Sciences CEO Daniel O'Day reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reports the vesting and disposal of restricted stock units.

Andrew Dickinson, CFO of Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold 9,513 shares of common stock at $78.03 per share on August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer of Gilead Sciences, Johanna Mercier, sold 5,490 shares of common stock at $73.98 per share on August 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the vesting and subsequent disposal of restricted stock units.

Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, reports the disposition and acquisition of common stock and restricted stock units on July 25, 2024.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the sale of 2,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences increases its holdings in Assembly Biosciences via a private placement, acquiring common stock and warrants.

Andrew Dickinson, CFO of Gilead Sciences, reports the vesting and subsequent disposal of restricted stock units.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units on June 10, 2024.

Gilead Sciences CEO Daniel O'Day reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units on June 10, 2024.

EVP Deborah H. Telman of Gilead Sciences reports the vesting and subsequent disposal of restricted stock units.